{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-24-000070","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.726890+00:00","generated_at":"2026-05-30T09:22:15.925118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M","bullets":["Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.","Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.","Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.","CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-24-000070","json":"https://secwatch.observer/filing/0001808805-24-000070.json","markdown":"https://secwatch.observer/filing/0001808805-24-000070.md","text":"https://secwatch.observer/filing/0001808805-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/0001808805-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/naut-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:22:15.925118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}